The Incentive Misalignment Audit
Good people plus broken incentives equals a broken system — follow the money, not the motives.
- Difficulty
- Advanced
- Time to result
- ~weeks to results
- Steps
- 6
- Confidence
- 85%
Wojcicki spent a decade on Wall Street analyzing healthcare and arrived at a structural diagnosis: the system is full of well-meaning people whose incentives point in the wrong direction. Nobody is rewarded for the absence of disease, so the CDC's diabetes prevention program runs on roughly $14 million a year while roughly $200 billion is spent managing diabetes. Employers won't fund prevention with a 15-year payback when the average employee stays three years — so the buck is passed in a game of hot potato. Her audit method is to trace who pays, over what horizon, and where the analytics talent is actually pointed. When she found that all of healthcare's new analytical power was aimed at billing optimization rather than keeping people out of hospital, the misalignment itself became the business thesis.
Origin
Working as a healthcare analyst — doing dialysis center roll-ups, modelling how to maximize collections by moving them into the emergency department, optimizing when to ask patients for insurance — Wojcicki attended a meeting on bill optimization and realized every analytical resource was aimed at extraction rather than health. That realization ended her Wall Street career and started 23andMe.
Core principles
- 01Nobody rewards the absence of a problem, so prevention is systematically underfunded everywhere.
- 02Assume good intent from individuals and bad design from the system — the incentives explain the behavior, not the people.
- 03The ROI horizon of the payer determines what gets funded, regardless of long-term value.
- 04The biggest business opportunities sit exactly where the incentives point away from the customer's interest.
How to run it
- 1
Separate the people from the system
Start from the assumption that participants are well-meaning. Wojcicki notes nobody suffers through seven years of medical school for the wrong incentives — which means bad outcomes are a design problem, not a character problem.
Pro tip This assumption is analytically useful, not just charitable: blaming people hides the mechanism you could actually change.
- 2
Trace who actually pays
Map the real payer, who is frequently not the person receiving the service. In US healthcare the employer, insurer, or PBM pays — so the consumer is never the customer.
Watch out Wherever the beneficiary is not the customer, expect the product to be designed for someone else.
- 3
Measure the payer's ROI horizon
Ask how long the payer holds the risk. An employer whose average tenure is three years will not fund a benefit that pays back over fifteen — the buck gets passed to whoever holds you next.
Pro tip The horizon mismatch, not stinginess, explains most refusals to invest in prevention.
- 4
Compare prevention spend to management spend
Put the two numbers side by side for the same condition. Roughly $14 million a year on CDC diabetes prevention against roughly $200 billion spent on diabetes reveals where the system's incentives truly sit.
Watch out An effective prevention program with tiny funding is a signal of misalignment, not of the program being unproven.
- 5
Follow the analytics talent
Look at where the smartest people and best data infrastructure are deployed. If they're optimizing billing rather than outcomes, you have located the system's real objective function.
- 6
Convert the gap into a thesis
The space between what's best for the customer and what's best for the payer is where a direct-to-consumer or realigned business can exist. That gap was the entire premise of 23andMe.
Watch out Confirm the customer will actually pay directly for what the system won't fund — otherwise the gap is real but unmonetizable.
In the wild
At a hedge fund working on healthcare, Wojcicki attended a meeting about bill optimization and realized that all of the industry's data and new analytics power was going into maximizing revenue per procedure rather than keeping people out of the hospital. Colleagues told her it was 'cute' that she thought about prevention, because nobody rewards the absence of a disease.
→ She left Wall Street and founded 23andMe on a direct-to-consumer model where the individual, not the payer, is the customer.
Wojcicki contrasts the CDC's diabetes prevention program — roughly $14 million a year, and incredibly effective — with roughly $200 billion spent on diabetes management, to show there is simply no financial comparison driving the system toward prevention.
→ The comparison became her standard proof that the system's incentives structurally favor managing disease over preventing it, independent of anyone's intentions.
Wojcicki explains that if the average employee stays three years, an employer has no reason to spend $10,000 today on something that pays back over fifteen years. The rational move is to pass the buck and hope someone else holds the cost — a game of hot potato.
→ The analysis identifies fragmented payment, not medical ignorance, as the reason preventative healthcare goes unfunded — and points at single-payer or direct-to-consumer as the structural fixes.
Common mistakes
Blaming the individuals
Concluding that doctors or insurers are villains leads to products that ask people to act against their own incentives. Wojcicki's whole point is that well-meaning people plus misaligned incentives reliably produce bad systems.
Ignoring the payer's time horizon
Pitching long-payback prevention to a short-horizon payer fails no matter how good the evidence. The ROI window is a hard constraint, not an education problem.
Finding the gap but not the payer
A gap between customer interest and system interest is only a business if someone will pay to close it. 23andMe worked because consumers would buy directly.
Is it for you?
Best for
Founders and analysts evaluating whether a dysfunctional industry contains a real business opportunity, particularly where the payer and the beneficiary are different parties.
Not ideal for
Simple consumer markets where the buyer, payer, and beneficiary are the same person and incentives are already aligned.
From the transcript
“All these people would kind of Pat me on the back and they're like it's so cute that you think about prevention but no one…”
“It was funded with like 14 million dollars every year for diabetes prevention and it's an incredibly effective program and then I'd compare that to…”
“It's full of people who really care and they're all incredibly well-meaning you don't go and suffer through seven years of medical school just to…”
“So if you're only going to be there for three years there has to be an Roi within three years if we're going to pay…”
From the episode
Anne Wojcicki: How 23andMe is Disrupting the Healthcare Industry
Anne Wojcicki